Tevogen Bio Stock (NASDAQ:TVGN)

Revenue Ownership Financials Chart

Previous Close

$1.22

52W Range

$0.26 - $3.09

50D Avg

$1.20

200D Avg

$1.23

Market Cap

$219.49M

Avg Vol (3M)

$950.00K

Beta

-0.67

Div Yield

-

TVGN Company Profile

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

18

IPO Date

Jan 05, 2022

Website

TVGN Performance

TVGN Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-53.56M	$-8.84K	$-13.72M
Net Income	$-13.73M	$-67.33K	$4.41M
EBITDA	$-53.56M	$188.71K	$-953.08K
Basic EPS	$-0.09	-	$0.04
Diluted EPS	$-0.09	-	$0.04

Fiscal year ends in Dec 24 | Currency in USD